<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39507365</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2667-193X</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Lancet regional health. Americas</Title><ISOAbbreviation>Lancet Reg Health Am</ISOAbbreviation></Journal><ArticleTitle>Clinical and functional assessment of SARS-CoV-2 sequelae among young marines - a panel study.</ArticleTitle><Pagination><StartPage>100909</StartPage><MedlinePgn>100909</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lana.2024.100909</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Long-term SARS-CoV-2 adverse health outcomes are of significant concern, especially among young adults with the potential for the greatest long-term morbidity. We sought to assess and characterize these outcomes in a cohort of Marines.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We used a cohort of US Marines from a previous longitudinal, prospective observational study of acute SARS-CoV-2, most of whom were enrolled prior to infection. A panel study was established to assess for post-acute sequelae of COVID-19 (PASC), defined as symptoms at least 4 weeks after symptom onset or diagnosis. Symptoms were assessed through questionnaires and validated quality of health metrics. Periodic US Marine Corps fitness testing metrics provided an additional standardized functional assessment and were compared to a pre-pandemic cohort.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">Globally dispersed Marine participants (n&#xa0;=&#xa0;899) seen an average of 330 days following initial enrollment were predominately male (n&#xa0;=&#xa0;825, 91.7%), White (n&#xa0;=&#xa0;613, 71.6%) or Black (n&#xa0;=&#xa0;149, 17.4%) with a median age of 18 years (interquartile range: 18-19). Among 798 SARS-CoV-2 infected participants, 197 (24.7%) developed PASC. The most prevalent symptoms were loss of taste and/or smell (n&#xa0;=&#xa0;82; 41.6%), shortness of breath (n&#xa0;=&#xa0;74; 37.6%), and cough (n&#xa0;=&#xa0;45; 22.8%). Those with PASC had higher rates and severity of somatic (p&#xa0;&lt;&#xa0;0.0001), general depressive (p&#xa0;&lt;&#xa0;0.0001), and anxiety (p&#xa0;=&#xa0;0.005) symptoms. Compared to a historic cohort of Marines, participants with PASC scored worse on their physical fitness assessments due to slower run times (p&#xa0;=&#xa0;0.002). Those with PASC continued to have decreased physical performance one year after completing initial training.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="UNASSIGNED">In this population of healthy young adult US Marines with mostly either asymptomatic or mild acute COVID-19, one fourth reported physical, cognitive, or psychiatric long-term sequelae of infection. The Marines affected with PASC showed evidence of long-term decrease in functional performance suggesting that SARS-CoV-2 infection may negatively affect health for a significant proportion of young adults.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED">Defense Health Agency and Defense Advanced Research Projects Agency.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Porter</LastName><ForeName>Chad K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beckett</LastName><ForeName>Charmagne G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Lindsey</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jakubski</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boulifard</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Megan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Peifang</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marayag</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marrone</LastName><ForeName>Amethyst</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nunez-Hernandez</LastName><ForeName>Edgar O</ForeName><Initials>EO</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vangeti</LastName><ForeName>Sindhu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Clare</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Yongchao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goforth</LastName><ForeName>Carl</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sealfon</LastName><ForeName>Stuart C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Letizia</LastName><ForeName>Andrew G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Naval Medical Research Command, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Reg Health Am</MedlineTA><NlmUniqueID>9918232503006676</NlmUniqueID><ISSNLinking>2667-193X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae of COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>SS serves as a consultant, acting Chief Scientific Officer and Chairman of the Scientific Advisory Board for GNOMX which is working on a diagnostic test for Long COVID. He is a shareholder and receives stock options in GNOMX Corp for his roles.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>11</Day><Hour>13</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>11</Day><Hour>13</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>7</Day><Hour>4</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39507365</ArticleId><ArticleId IdType="pmc">PMC11539644</ArticleId><ArticleId IdType="doi">10.1016/j.lana.2024.100909</ArticleId><ArticleId IdType="pii">S2667-193X(24)00236-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>